Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Theratope, Biomira Inc.

M A Morse1

  • 1Duke University Medical Center, Department of Surgery, Immunology and Pathology, Durham, NC 27710, USA. m.morse@cgct.duke.edu

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary

Active specific immunotherapy using the Theratope vaccine shows promise for cancer treatment. This vaccine stimulates immune responses against mucin-expressing tumors, with early studies suggesting survival benefits in breast cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial.

ESMO gastrointestinal oncology·2026
Same author

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

Journal for immunotherapy of cancer·2019
Same author

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018
Same author

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

The British journal of dermatology·2018
Same author

X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.

Cell death & disease·2016

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Active specific immunotherapy offers a complementary approach to traditional cancer treatments for high-risk patients.
  • Tumor-associated antigens and adjuvants are key components for stimulating therapeutic immune responses.
  • The Theratope vaccine utilizes a synthetic mucin glycan epitope (STn) conjugated to a carrier molecule.

Purpose of the Study:

  • To evaluate the efficacy of the Theratope vaccine in patients with mucin-expressing tumors.
  • To assess the immune response, including antibody and T-cell activation, to the Theratope vaccine.
  • To investigate the potential survival benefit of Theratope vaccine in combination with cyclophosphamide.

Main Methods:

  • Development of the Theratope vaccine using a synthetic STn glycan mimic conjugated to keyhole limpet hemocyanin.
  • Administration of the Theratope vaccine to patients with mucin-expressing tumors.
  • Pretreatment with intravenous cyclophosphamide to inhibit suppressor T-cells and augment the immune response.
  • Phase II and ongoing Phase III clinical trials in breast cancer patients, with potential applicability in ovarian and gastrointestinal cancers.

Main Results:

  • Murine and human studies demonstrated stimulation of anti-STn antibodies and mucin-specific T-cell responses.
  • Phase II studies indicated a survival benefit for breast cancer patients treated with the Theratope vaccine post-cyclophosphamide.
  • A multinational Phase III study is currently evaluating the vaccine in metastatic breast cancer patients with stable disease or clinical response.

Conclusions:

  • The Theratope vaccine is a promising active immunotherapy agent for mucin-expressing cancers.
  • Combining the Theratope vaccine with cyclophosphamide may enhance anti-tumor immune responses and improve patient survival.
  • Further clinical trials are warranted to confirm the efficacy and applicability of this vaccine in various cancer types.

Related Experiment Videos